David Sholehvar's most recent trade in Invitae Corp was a trade of 850,000 Common Stock done . Disclosure was reported to the exchange on Nov. 13, 2023.
Stock | Client Name | Client Category | Action | Reported to Exchange | Quantity | Post Transaction Holding | Traded % | Avg. Price | Value | Security Type |
---|---|---|---|---|---|---|---|---|---|---|
Invitae Corp | David B. Sholehvar | Chief Operating Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 13 Nov 2023 | 850,000 | 850,000 (0%) | 0% | 0 | Common Stock | |
Neogenomics Inc. | David Sholehvar | President, Clinical Services | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 01 Aug 2022 | 25,826 | 25,826 | - | - | Stock Option (Right to Buy) | |
Neogenomics Inc. | David Sholehvar | President, Clinical Services | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 01 Aug 2022 | 12,352 | 43,216 (0%) | 0% | 0 | Common Stock | |
Neogenomics Inc. | David Sholehvar | President, Clinical Services | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 01 Apr 2022 | 66,372 | 66,372 | - | - | Stock Option (Right to Buy) | |
Neogenomics Inc. | David Sholehvar | President, Clinical Services | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 01 Apr 2022 | 30,864 | 30,864 (0%) | 0% | 0 | Common Stock |